Important information regarding cookies and
By using this website, you consent to the use of cookies in accordance with the IMB Cookie Policy. For more information on cookies, see our Cookie Policy.
Full Version | Search

The Irish Medicines Board -

IMB Logo

Sabril (vigabatrin) - Important Safety Information from sanofi-aventis as approved by the Irish Medicines Board

05 July 2010

Important safety information communication from sanofi-aventis on abnormal brain MRI findings and movement disorders in patients treated with Sabril® (Vigabatrin).

Important Safety Information - Sabril (vigabatrin)

Date Printed: 18 April 2014

© Irish Medicines Board 2014 | Developed by Engine Solutions

Address: Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Ireland.
Tel: 353-1-676 4971